{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/shingles/prescribing-information/zostavax/","result":{"pageContext":{"chapter":{"id":"1223613b-f5a6-5da6-a311-275f5d6181b2","slug":"zostavax","fullItemName":"Zostavax","depth":2,"htmlHeader":"<!-- begin field 6b3dcc75-c741-4bb2-a9c4-aacc00ac334e --><h2>Zostavax®</h2><!-- end field 6b3dcc75-c741-4bb2-a9c4-aacc00ac334e -->","summary":"","htmlStringContent":"<!-- begin item 7d4dd897-1a40-4527-81dd-aacc00ac3303 --><!-- end item 7d4dd897-1a40-4527-81dd-aacc00ac3303 -->","topic":{"id":"012e484d-8c14-5168-bb5d-e5acb7d4571a","topicId":"2969a8ac-cb7f-4569-be79-822e6009081a","topicName":"Shingles","slug":"shingles","lastRevised":"Last revised in October 2020","chapters":[{"id":"eeb1b918-6c05-5340-b348-ce2809516623","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8ad8b1b2-36bb-5262-ab5a-05763d6e4c7d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b1aed669-8481-5315-ab58-4bb18606e360","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8fef2c66-91dc-57c6-8cd3-4e4eff8d7727","slug":"changes","fullItemName":"Changes"},{"id":"ea603e45-ec07-5201-a182-ebef4c48ef6b","slug":"update","fullItemName":"Update"}]},{"id":"81feec28-1a5d-5a24-9c52-bee13821b03b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bb672f83-c2bd-5dd7-9934-78f09729db48","slug":"goals","fullItemName":"Goals"},{"id":"2036bd3f-37bc-5cea-887d-55c3fc68c7cf","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cc04b460-a0d8-5e8d-b8d0-c044947b4bd6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ee3573cb-38d5-5d4c-9c9d-cd274242d964","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"52999d3b-9cce-59c5-b588-1f7ad7de33e2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"40a91fd6-3c01-5713-85ad-0a5c4379eab9","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"04a0af22-814d-5b14-b28c-7916f1772a4d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"097dfec6-754a-54a8-9d96-44e1c5704248","slug":"definition","fullItemName":"Definition"},{"id":"f20034b1-ae3e-505b-ac16-3e11f2a6653e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e92f0243-b1ac-50d9-a31a-a07a4c61c5a7","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b6f8c581-b332-5d26-ba45-ccfb7189a387","slug":"complications","fullItemName":"Complications"},{"id":"012c8f32-e9cf-5897-a695-4c21cd28ae5d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"81f3feff-d640-5ee2-83fa-af1a4e8b586a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"56b89dcf-d466-50f3-a8a0-3a9477ef3362","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"01bc96b7-ea05-59b9-963a-16b2722b9367","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"acd9aec2-87d6-5084-bd3a-5c0b1d164ab4","fullItemName":"Management","slug":"management","subChapters":[{"id":"9872f447-6f59-502d-b6cb-a0fae6d2c085","slug":"management","fullItemName":"Scenario: Management"},{"id":"9ecdcc36-4fec-5b60-aa42-2032f2c406a4","slug":"prevention","fullItemName":"Scenario: Prevention"}]},{"id":"929d18e1-e1f0-5d08-8c55-d289b349a9fd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4445c1da-4f7a-5f12-a909-0112bbd72453","slug":"antiviral-drugs","fullItemName":"Antiviral drugs"},{"id":"1223613b-f5a6-5da6-a311-275f5d6181b2","slug":"zostavax","fullItemName":"Zostavax"}]},{"id":"67979756-a00f-5f10-a93e-81509b35e1a8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"625749c2-4e09-57ba-bdee-cd206d8b02d5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"377ce207-6229-5548-aef7-a637f176a94e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19ac0831-d4e2-52c3-b127-e78b1f26fb6f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d46d7aff-a113-50d5-afa1-3310aad844d7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d23205e9-41c9-5c70-a9f9-5ce3cfae633a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"cf98894b-c083-59fd-8150-f390845960f1","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a52b727c-ba28-5973-9e3c-e4882a883593","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"929d18e1-e1f0-5d08-8c55-d289b349a9fd","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"8122bf7b-6d10-5566-8dc0-4ce8601e34a3","slug":"indication-recommended-dose","fullItemName":"Indication and recommended dose","depth":3,"htmlHeader":"<!-- begin field af2a8c08-d64a-488b-a4d9-aacc00ac714e --><h3>What is the licensed indication and recommended dose?</h3><!-- end field af2a8c08-d64a-488b-a4d9-aacc00ac714e -->","summary":"","htmlStringContent":"<!-- begin item eac4bb77-75ff-487d-89e8-aacc00ac7127 --><!-- begin field 059c186d-7db8-4fb1-be02-aacc00ac714e --><ul><li><strong>Zostavax® is indicated for the prevention of herpes zoster (shingles) and herpes zoster-related post-herpetic neuralgia in people aged 50 years of age or older.</strong><ul><li>It is currently the only licensed shingles vaccine in the UK and contains live attenuated varicella zoster virus. </li><li>Although Zostavax® is licensed for use from age 50 years and is effective in this age group, the burden of shingles disease is generally not as severe in those aged 50–69 years when compared with older ages. Furthermore, given that the duration of protection is not known to last for more than ten years and the need for a second dose is not known, the vaccine is not recommended to be offered routinely in people younger than 70 years of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2018</a>].  </li><li>Administration of Zostavax® after 80 years of age is less cost effective due to the reducing efficacy of the vaccine as age increases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2018</a>]. </li></ul></li><li><strong>The recommended dose for adults aged 70–79 years is</strong> a single 0.65 mL dose administered subcutaneously or intramuscularly, preferably into the deltoid region of the upper arm.<ul><li>For people with a bleeding disorder, Zostavax® should be given by deep subcutaneous injection to reduce the risk of bleeding.</li><li>Zostavax® can be administered at any time of year and does not need to be administered during the influenza vaccine season. </li><li>For more information on administration of Zostavax®, see the chapter on <a data-hyperlink-id=\"d7e6cdad-eff0-48f7-90f5-aacc0055e423\" href=\"https://www.gov.uk/government/publications/shingles-herpes-zoster-the-green-book-chapter-28a\">Shingles (herpes zoster)</a> in <em>Immunisation against infectious disease</em> (the 'Green book'), published by Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2016</a>], the PHE guideline <em>Vaccination against shingles. Information for healthcare professionals </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2018</a>], and the manufacturer's <a data-hyperlink-id=\"5ce5d4e4-09fa-43ba-aedf-aacc00d34e97\" href=\"https://www.medicines.org.uk/emc/product/6101/smpc#PRODUCTINFO\">Summary of Product Characteristics</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019b</a>]</p><!-- end field 059c186d-7db8-4fb1-be02-aacc00ac714e --><!-- end item eac4bb77-75ff-487d-89e8-aacc00ac7127 -->","subChapters":[]},{"id":"6b6591d8-79f2-5f7b-9ad6-9df052105503","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field d61f6dd3-fd18-4863-8077-aacc00ac8981 --><h3>What are the contraindications and cautions?</h3><!-- end field d61f6dd3-fd18-4863-8077-aacc00ac8981 -->","summary":"","htmlStringContent":"<!-- begin item 8a408941-d40e-4d85-99e6-aacc00ac8962 --><!-- begin field d3af173a-8ee6-4375-aa84-aacc00ac8981 --><ul><li><strong>Zostavax® should not be given to </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019b</a>]<strong>:</strong><ul><li>People with a history of hypersensitivity to the active substance or to any of the excipients or trace residuals (for example neomycin).</li><li>People who have primary and acquired immunodeficiency states due to conditions such as acute and chronic leukaemias, lymphoma, other conditions affecting the bone marrow or lymphatic system, immunosuppression due to HIV/AIDS, or cellular immune deficiencies.<ul><li>See the chapter on <a data-hyperlink-id=\"65872379-b5e0-4aaf-990a-aad2009bb024\" href=\"https://www.gov.uk/government/publications/shingles-herpes-zoster-the-green-book-chapter-28a\">Shingles (herpes zoster)</a> in <em>Immunisation against infectious disease</em> (the 'Green book'), published by Public Health England (PHE), for more information.</li></ul></li><li>People on immunosuppressive therapy, including high-dose corticosteroids. However, Zostavax® is not contraindicated for use in people who are receiving topical or inhaled corticosteroids or low-dose systemic corticosteroids, or in people who are receiving corticosteroids as replacement therapy (for example for adrenal insufficiency).<ul><li>See the chapter on <a data-hyperlink-id=\"d7e6cdad-eff0-48f7-90f5-aacc0055e423\" href=\"https://www.gov.uk/government/publications/shingles-herpes-zoster-the-green-book-chapter-28a\">Shingles (herpes zoster)</a> in <em>Immunisation against infectious disease</em> (the 'Green book') for more information.</li></ul></li><li>People who have ​​​​​​active untreated tuberculosis.</li><li>Pregnant women — Zostavax® is not licenced for use in women of childbearing age. However, PHE advises that the weakened varicella-zoster virus in Zostavax® has not been linked to specific problems in babies born to women who have received vaccines containing this virus whilst pregnant.<ul><li>See the PHE guidance on <a data-hyperlink-id=\"b494f856-05af-4ae9-be37-aaca00c4d7f1\" href=\"https://www.gov.uk/government/publications/vaccine-in-pregnancy-advice-for-pregnant-women/chickenpox-and-shingles-vaccines-advice-for-pregnant-women\">Chickenpox and shingles vaccines: advice for pregnant women</a>, available at <a data-hyperlink-id=\"e610bd2e-1d48-494b-b946-a93100a1b77a\" href=\"https://www.gov.uk/\">www.gov.uk</a>, for more information.</li></ul></li></ul></li><li><strong>Zostavax® should be used with caution in </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019b</a>]<strong>:</strong><ul><li>People with an acute illness or infection — vaccination should be postponed until they have recovered fully. This is to avoid confusing the diagnosis of any acute illness by wrongly attributing any sign or symptoms to the adverse effects of the vaccine.</li><li>People who are being treated with either oral or intravenous antivirals (such as aciclovir) — vaccination should be delayed until 48 hours after cessation of antiviral treatment. This is due to the potential to lower effectiveness of the vaccine as the treatment may reduce response to the vaccine. The use of topical aciclovir is not a contraindication to vaccination.</li><li>People who have shingles or post-herpetic neuralgia — Zostavax® is not recommended for the treatment of shingles or post-herpetic neuralgia. Vaccination should be delayed until symptoms have stopped. In immunocompetent people who develop shingles, vaccination should be delayed for one year. People who have two or more episodes of shingles in one year should have immunological investigation prior to vaccination. It may be necessary to seek specialist advice. </li></ul></li></ul><!-- end field d3af173a-8ee6-4375-aa84-aacc00ac8981 --><!-- end item 8a408941-d40e-4d85-99e6-aacc00ac8962 -->","subChapters":[]},{"id":"52fa3c0e-51b7-5d6d-91e5-f08e60b79459","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 2e2e542e-c3fb-4951-8cdf-aacc00ac9aaf --><h3>What are the possible adverse effects?</h3><!-- end field 2e2e542e-c3fb-4951-8cdf-aacc00ac9aaf -->","summary":"","htmlStringContent":"<!-- begin item 9d4b9d17-17f1-45d3-b3fb-aacc00ac9a96 --><!-- begin field a72c243e-ab7f-40ef-8ad7-aacc00ac9aaf --><ul><li><strong>The most common adverse effects of Zostavax®</strong> are injection-site reactions, including erythema, pain and tenderness, itching, swelling, rash, induration, haematoma, warmth, and pyrexia. Other common adverse effects are headache, arthralgia, myalgia, and pain in extremity. </li><li><strong>Other adverse effects of Zostavax® include:</strong><ul><li>Uncommon — lymphadenopathy (cervical, axillary) and nausea.</li><li>Rare — injection site urticaria and hypersensitivity reactions (including anaphylactic reactions).</li><li>Very rare — infections (including varicella and herpes zoster [vaccine strain]) and necrotizing retinitis (in people on immunosuppressive therapy).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019b</a>]</p><!-- end field a72c243e-ab7f-40ef-8ad7-aacc00ac9aaf --><!-- end item 9d4b9d17-17f1-45d3-b3fb-aacc00ac9a96 -->","subChapters":[]},{"id":"97d2aa43-e1d3-5b23-908d-90e8019b4f07","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field efc4bbae-be15-4db8-bb78-aacc00aca8cc --><h3>What are the possible drug interactions with Zostavax®?</h3><!-- end field efc4bbae-be15-4db8-bb78-aacc00aca8cc -->","summary":"","htmlStringContent":"<!-- begin item 6302abc9-683b-46ae-9454-aacc00aca8b2 --><!-- begin field f452f8b7-fe7f-431a-ad36-aacc00aca8cc --><ul><li><strong>Interactions with other vaccines:</strong><ul><li>Zostavax® can be administered concurrently with inactivated influenza vaccine as separate injections and at different body sites.</li><li>Concurrent use of Zostavax® and a 23-valent pneumococcal polysaccharide vaccine resulted in reduced immunogenicity of Zostavax® in a small clinical trial. However, data collected in a large observational study did not indicate increased risk for developing herpes zoster after concurrent administration of the two vaccines.</li><li>The manufacturer advises that no data are currently available regarding concurrent use with other vaccines.</li></ul></li><li><strong>Interactions with antiviral medications:</strong><ul><li>The manufacturer advises that concurrent use of Zostavax® and antiviral medications known to be effective against varicella-zoster virus has not been evaluated.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019b</a>]</p><!-- end field f452f8b7-fe7f-431a-ad36-aacc00aca8cc --><!-- end item 6302abc9-683b-46ae-9454-aacc00aca8b2 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}